

Management of latent *Mycobacterium tuberculosis* in
low tuberculosis burden countries

European Respiratory Journal

46, 1563-1576

DOI: 10.1183/13993003.01245-2015

Citation Report

#	ARTICLE	IF	CITATIONS
1	Tuberculosis Infection Control in Healthcare Settings. , 0, , 361-379.		0
2	Accelerating tuberculosis elimination in low-incidence settings: the role of genomics. European Respiratory Journal, 2015, 46, 1841-1843.	3.1	0
3	Management of drug resistant TB in patients with HIV co-infection. Expert Opinion on Pharmacotherapy, 2015, 16, 2737-2750.	0.9	10
4	Experience of health professionals in care of the homeless population with tuberculosis. Revista Da Escola De Enfermagem Da U S P, 2016, 50, 808-815.	0.3	20
5	Policies and practices on the programmatic management of latent tuberculous infection: global survey. International Journal of Tuberculosis and Lung Disease, 2016, 20, 1566-1571.	0.6	13
6	Tuberculosis Vaccines. , 2016, , 363-383.		0
7	Systemic Expression of Notch Ligand Delta-Like 4 during Mycobacterial Infection Alters the T Cell Immune Response. Frontiers in Immunology, 2016, 7, 527.	2.2	15
8	Comparing isogenic strains of Beijing genotype <i>Mycobacterium tuberculosis</i> after acquisition of Isoniazid resistance: A proteomics approach. Proteomics, 2016, 16, 1376-1380.	1.3	11
9	Implementing tuberculosis entry screening for asylum seekers: the Groningen experience. European Respiratory Journal, 2016, 48, 261-264.	3.1	21
10	Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infectious Diseases, The, 2016, 16, 1185-1192.	4.6	151
11	Diagnosis and management of latent tuberculosis. Current Opinion in Infectious Diseases, 2016, 29, 205-211.	1.3	14
12	Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis. European Respiratory Journal, 2016, 48, 1751-1763.	3.1	165
13	Changes in the Membrane-Associated Proteins of Exosomes Released from Human Macrophages after Mycobacterium tuberculosis Infection. Scientific Reports, 2016, 6, 37975.	1.6	51
14	Diabetes mellitus and latent tuberculosis infection: a systemic review and meta-analysis. Clinical Infectious Diseases, 2017, 64, ciw836.	2.9	84
15	Risk of Active Tuberculosis in Patients with Cancer: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 2017, 64, ciw838.	2.9	73
16	Latent <i>Mycobacterium tuberculosis</i> Infection and Interferon-Gamma Release Assays. Microbiology Spectrum, 2016, 4, .	1.2	71
17	Risk of Tuberculosis Among Patients on Dialysis. Medicine (United States), 2016, 95, e3813.	0.4	15
18	From latent to active TB: are IGRAs of any use?: Table 1. Thorax, 2016, 71, 585-586.	2.7	6

#	ARTICLE	IF	CITATIONS
19	Annual risk of tuberculosis infection in rural China: a population-based prospective study. <i>European Respiratory Journal</i> , 2016, 48, 168-178.	3.1	37
20	Reactivation tuberculosis: role of surveillance. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 501-509.	2.0	2
21	Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. <i>Journal of Travel Medicine</i> , 2016, 23, .	1.4	10
22	Advancing global programmatic management of latent tuberculosis infection for at risk populations. <i>European Respiratory Journal</i> , 2016, 47, 1327-1330.	3.1	22
23	Preliminary data on precision of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 48, 953-954.	3.1	6
24	The Challenge of Latent TB Infection. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 931.	3.8	31
25	New tests for detection of <i>Mycobacterium tuberculosis</i> infection: sufficient to meet the WHO 2035 targets?. <i>Future Microbiology</i> , 2016, 11, 1101-1104.	1.0	2
26	First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus. <i>Journal of Infection</i> , 2016, 73, 588-597.	1.7	101
27	Rifampicin resistance after treatment for latent tuberculous infection: a systematic review and meta-analysis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2016, 20, 1065-1071.	0.6	33
28	Rifapentine for the treatment of latent tuberculosis. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1253-1261.	1.3	1
29	Risk of self-reported symptoms or diagnosis of active tuberculosis in relationship to low body mass index, diabetes and their co-occurrence. <i>Tropical Medicine and International Health</i> , 2016, 21, 1272-1281.	1.0	2
30	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e147-e195.	2.9	916
31	Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands. <i>European Respiratory Journal</i> , 2016, 48, 1420-1428.	3.1	26
32	Preventing and controlling tuberculosis among refugees in Europe: more is needed. <i>European Respiratory Journal</i> , 2016, 48, 272-274.	3.1	19
33	Preventing and controlling tuberculosis among refugees in Europe: more needed for high-risk populations. <i>European Respiratory Journal</i> , 2016, 48, 274-276.	3.1	7
34	Tuberculosis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16076.	18.1	830
35	Recent developments in the diagnosis and management of tuberculosis. <i>Npj Primary Care Respiratory Medicine</i> , 2016, 26, 16078.	1.1	58
36	Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care. <i>European Respiratory Journal</i> , 2016, 48, 1278-1281.	3.1	7

#	ARTICLE	IF	CITATIONS
37	Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance. <i>European Respiratory Journal</i> , 2016, 48, 1282-1287.	3.1	20
38	Lack of Response to <scp>HBHA</scp> in <scp>HIV</scp>-infected Patients with Latent Tuberculosis Infection. <i>Scandinavian Journal of Immunology</i> , 2016, 84, 344-352.	1.3	23
39	Prevalence and predictors of latent tuberculosis infection among Italian State Policemen engaged in assistance to migrants: a national cross-sectional study. <i>BMJ Open</i> , 2016, 6, e012011.	0.8	2
40	Reply to a comment on Tuberculosis and the traveller: evaluating and reducing risk through travel consultation. <i>Journal of Travel Medicine</i> , 2016, 23, taw031.	1.4	8
41	The transmission of <i>Mycobacterium tuberculosis</i> in high burden settings. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 227-238.	4.6	149
42	Call for urgent actions to ensure access to early diagnosis and care of tuberculosis among refugees. <i>European Respiratory Journal</i> , 2016, 47, 1345-1347.	3.1	34
43	Predicting active tuberculosis progression by RNA analysis. <i>Lancet</i> , The, 2016, 387, 2268-2270.	6.3	9
44	First independent evaluation of QuantiFERON-TB Plus performance. <i>European Respiratory Journal</i> , 2016, 47, 1587-1590.	3.1	87
45	Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. <i>European Respiratory Journal</i> , 2016, 47, 394-402.	3.1	136
46	Diagnostics for latent TB infection: incremental, not transformative progress. <i>European Respiratory Journal</i> , 2016, 47, 704-706.	3.1	31
47	Monitoring latent tuberculosis infection diagnosis and management in the Netherlands. <i>European Respiratory Journal</i> , 2016, 47, 1492-1501.	3.1	32
48	How much is too much alcohol in tuberculosis?. <i>European Respiratory Journal</i> , 2017, 49, 1601468.	3.1	24
49	Prevalence of tuberculosis infection in healthcare workers of the public hospital network in Medellín, Colombia: a Bayesian approach. <i>Epidemiology and Infection</i> , 2017, 145, 1095-1106.	1.0	5
50	Tuberculosis in children. <i>Paediatrics and Child Health (United Kingdom)</i> , 2017, 27, 109-115.	0.2	3
51	Optimizing the management of children with latent tuberculosis infection. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 341-349.	2.0	4
52	Dopamine-assisted fixation of drug-loaded polymeric multilayers to osteoarticular implants for tuberculosis therapy. <i>Biomaterials Science</i> , 2017, 5, 730-740.	2.6	22
53	Treatment completion for latent tuberculosis infection: a retrospective cohort study comparing 9 months of isoniazid, 4 months of rifampin and 3 months of isoniazid and rifampentine. <i>BMC Infectious Diseases</i> , 2017, 17, 146.	1.3	35
54	Tuberculosis elimination and the challenge of latent tuberculosis. <i>Presse Medicale</i> , 2017, 46, e13-e21.	0.8	48

#	ARTICLE	IF	CITATIONS
55	Tuberculosis Associated with HIV Infection. <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	51
56	Agents of change: The role of healthcare workers in the prevention of nosocomial and occupational tuberculosis. <i>Presse Medicale</i> , 2017, 46, e53-e62.	0.8	41
57	The cursed duet today: Tuberculosis and HIV-coinfection. <i>Presse Medicale</i> , 2017, 46, e23-e39.	0.8	50
58	The global dynamics of diabetes and tuberculosis: the impact of migration and policy implications. <i>International Journal of Infectious Diseases</i> , 2017, 56, 45-53.	1.5	37
59	Efficacy of Treatment for Latent Tuberculosis in Patients Undergoing Treatment with a Tumor Necrosis Factor Antagonist. <i>Annals of the American Thoracic Society</i> , 2017, 14, 690-697.	1.5	23
60	Treatment of Latent Tuberculosis Infection. <i>Microbiology Spectrum</i> , 2017, 5, .	1.2	19
61	Post-migration follow-up of migrants identified to be at increased risk of developing tuberculosis at pre-migration screening: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 770-779.	4.6	38
62	Targeting isocitrate lyase for the treatment of latent tuberculosis. <i>Drug Discovery Today</i> , 2017, 22, 1008-1016.	3.2	40
63	Tuberculosis in migrants in low-incidence countries: epidemiology and intervention entry points. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 624-636.	0.6	113
64	Eliminating latent tuberculosis in low-burden settings: are the principal beneficiaries to be disadvantaged groups or the broader population?. <i>Journal of Medical Ethics</i> , 2017, 43, 632-636.	1.0	7
65	Standard operating procedures for tuberculosis care. <i>European Respiratory Journal</i> , 2017, 49, 1700515.	3.1	6
66	Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries. <i>European Respiratory Journal</i> , 2017, 49, 1602242.	3.1	11
67	Treatment of Pulmonary Tuberculosis. , 2017, , 35-90.		3
68	Management of Tuberculosis in Special Populations. , 2017, , 141-190.		1
69	Policy and practice of programmatic management of latent tuberculosis infection in The Netherlands. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2017, 7, 40-48.	0.6	14
70	World TB Day 2017: Strengthening the fight against TB. <i>Presse Medicale</i> , 2017, 46, e1-e4.	0.8	2
71	Impact of interferon- γ release assay on the latent tuberculosis cascade of care: a population-based study. <i>European Respiratory Journal</i> , 2017, 49, 1601546.	3.1	6
72	Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 792-800.	0.6	16

#	ARTICLE	IF	CITATIONS
73	Prevalence of Latent Mycobacterium Tuberculosis Infection (LTBI) in Saudi Arabia; Population based survey. <i>International Journal of Infectious Diseases</i> , 2017, 60, 11-16.	1.5	19
74	Handbook of Tuberculosis. , 2017, , .		3
75	Shifting from tuberculosis control to elimination: Where are we? What are the variables and limitations? Is it achievable?. <i>International Journal of Infectious Diseases</i> , 2017, 56, 30-33.	1.5	22
76	Cholesterol metabolism: a potential therapeutic target in <i>Mycobacteria</i> . <i>British Journal of Pharmacology</i> , 2017, 174, 2194-2208.	2.7	32
77	Tuberculosis screening using <i>IGRA</i> and chest computed tomography in patients with inflammatory bowel disease: A retrospective study. <i>Journal of Digestive Diseases</i> , 2017, 18, 23-30.	0.7	15
78	Resistance to First-Line Antituberculosis Drugs in Washington State by Region of Birth and Implications for Latent Tuberculosis Treatment Among Foreign-Born Individuals. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 543-549.	0.6	2
79	Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data. <i>Revista Portuguesa De Pneumologia</i> , 2017, 23, 27-30.	0.7	11
80	Screening, prophylaxis and counselling before the start of biological therapies: A practical approach focused on IBD patients. <i>Digestive and Liver Disease</i> , 2017, 49, 1289-1297.	0.4	22
81	Prevention of tuberculosis transmission through medical surveillance systems. <i>Lancet Public Health</i> , The, 2017, 2, e439-e440.	4.7	1
82	Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2017, 50, 1700157.	3.1	75
83	Burden of non-adherence to latent tuberculosis infection drug therapy and the potential cost-effectiveness of adherence interventions in Canada: a simulation study. <i>BMJ Open</i> , 2017, 7, e015108.	0.8	20
85	Latent tuberculosis infection in rural China: who will develop tuberculosis?. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 1007-1008.	4.6	0
86	Use of interferon-gamma release assay and tuberculin skin test in diagnosing tuberculosis in Lithuanian adults: A comparative analysis. <i>Medicina (Lithuania)</i> , 2017, 53, 159-165.	0.8	1
87	Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation. <i>European Respiratory Journal</i> , 2017, 50, 1602505.	3.1	27
88	Negative latent tuberculosis at time of incarceration: identifying a very high-risk group for infection. <i>Epidemiology and Infection</i> , 2017, 145, 2491-2499.	1.0	16
89	Treatment of Latent Tuberculosis Infection. <i>Annals of Internal Medicine</i> , 2017, 167, 248.	2.0	149
90	The Utility of Immunohistochemistry in Mycobacterial Infection. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1364-1370.	2.1	13
92	The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know?. <i>Respirology</i> , 2017, 22, 1062-1072.	1.3	9

#	ARTICLE	IF	CITATIONS
93	Analytical evaluation of QuantiFERON- Plus and QuantiFERON- Gold In-tube assays in subjects with or without tuberculosis. <i>Tuberculosis</i> , 2017, 106, 38-43.	0.8	89
94	Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2028-2034.	1.3	9
95	Quality of tuberculosis care in high burden countries: the urgent need to address gaps in the care cascade. <i>International Journal of Infectious Diseases</i> , 2017, 56, 111-116.	1.5	136
96	Multidrug-resistant tuberculosis and migration to Europe. <i>Clinical Microbiology and Infection</i> , 2017, 23, 141-146.	2.8	58
97	Preventive therapy for latent tuberculosis infectionâ€”the promise and the challenges. <i>International Journal of Infectious Diseases</i> , 2017, 56, 68-76.	1.5	118
98	Risk for latent and active tuberculosis in Germany. <i>Infection</i> , 2017, 45, 283-290.	2.3	22
99	Tuberculosis and latent tuberculous infection screening of migrants in Europe: comparative analysis of policies, surveillance systems and results. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 840-851.	0.6	71
100	Children under 5â€¦years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker. <i>European Respiratory Journal</i> , 2017, 50, 1701414.	3.1	21
101	<sc>SIRCLE</sc>: a randomised controlled cost comparison of selfâ€¦administered shortâ€¦course isoniazid and rifapentine for costâ€¦effective latent tuberculosis eradication. <i>Internal Medicine Journal</i> , 2017, 47, 1433-1436.	0.5	8
102	Tuberculosis Associated with HIV Infection. , 2017, , 577-594.		1
103	Latent Mycobacterium tuberculosis Infection and Interferon-Gamma Release Assays. , 2017, , 379-388.		0
104	Treatment of Latent Tuberculosis Infection. , 2017, , 67-100.		0
105	Self-administered Versus Directly Observed Once-Weekly Isoniazid and Rifapentine Treatment of Latent Tuberculosis Infection. <i>Annals of Internal Medicine</i> , 2017, 167, 689.	2.0	108
106	Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. <i>PLoS ONE</i> , 2017, 12, e0183846.	1.1	31
107	Screening for latent tuberculous infection in people living with HIV infection in Auckland, New Zealand. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 1008-1012.	0.6	5
108	Methodological considerations for economic modelling of latent tuberculous infection screening in migrants. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 977-989.	0.6	7
109	Tuberculosis treatment. <i>Jornal Brasileiro De Pneumologia</i> , 2017, 43, 472-486.	0.4	65
110	Latent tuberculosis in childhood: tolerability of two different therapeutic approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 359-365.	2.0	6

#	ARTICLE	IF	CITATIONS
111	Too little too late: Waiting for TB to come. Indian Journal of Tuberculosis, 2018, 65, 106-108.	0.3	1
112	ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update. European Respiratory Journal, 2018, 51, 1702678.	3.1	50
113	High rate of latent tuberculosis treatment completion in immigrants seeking asylum in Sweden. Infectious Diseases, 2018, 50, 678-686.	1.4	8
114	Epidemiological, clinical and mechanistic perspectives of tuberculosis in older people. Respirology, 2018, 23, 567-575.	1.3	41
115	Indicaciones de quimioprofilaxis en la infección por Mycobacterium tuberculosis . Interpretación de las pruebas diagnósticas. Medicine, 2018, 12, 3153-3156.	0.0	0
116	QuantIFERON-TB Gold In-Tube as a Confirmatory Test for Tuberculin Skin Test in Tuberculosis Contact Tracing: A Noninferiority Clinical Trial. Clinical Infectious Diseases, 2018, 66, 396-403.	2.9	18
117	Tuberculosis prevention and care in Korea: Evolution of policy and practice. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2018, 11, 28-36.	0.6	75
118	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune) Tj ETQq1 1 0.784314 rgBT /Overlock 2.8 139 24. S10-S20.	2.8	139
119	Barriers to treatment adherence for individuals with latent tuberculosis infection: A systematic search and narrative synthesis of the literature. International Journal of Health Planning and Management, 2018, 33, e416-e433.	0.7	28
120	The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. European Respiratory Journal, 2018, 51, 1701488.	3.1	25
121	Screening for latent tuberculosis infection among patients with rheumatoid arthritis in the era of biologics and targeted synthetic disease-modifying anti-rheumatic drugs in India, a high-burden TB country: The importance of Mantoux and Quantiferon Gold tests. International Journal of Rheumatic Diseases, 2018, 21, 1563-1571.	0.9	12
122	Migration, TB control and elimination: Whom to screen and treat. Pulmonology, 2018, 24, 99-105.	1.0	19
123	Tuberculosis in the elderly: Why inflammation matters. Experimental Gerontology, 2018, 105, 32-39.	1.2	58
124	Effect of Genetic Variation of NAT2 on Isoniazid and SLCO1B1 and CES2 on Rifampin Pharmacokinetics in Ghanaian Children with Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	26
126	National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area. European Respiratory Journal, 2018, 51, 1701226.	3.1	19
127	Tuberculosis elimination: a dream or a reality? The case of Oman. European Respiratory Journal, 2018, 51, 1702027.	3.1	18
128	High-density lipoprotein suppresses tumor necrosis factor alpha production by mycobacteria-infected human macrophages. Scientific Reports, 2018, 8, 6736.	1.6	23
129	The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. Lancet Respiratory Medicine, the, 2018, 6, 299-314.	5.2	311

#	ARTICLE	IF	CITATIONS
130	The World Health Organization standards for tuberculosis care and management. <i>European Respiratory Journal</i> , 2018, 51, 1800098.	3.1	57
131	Mycobacterium Infections in Rheumatoid Arthritis (Tuberculosis and Nontuberculous) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 702		
132	Preventing Tuberculosis in a Low Incidence Setting: Evaluation of a Multi-lingual, Online, Educational Video on Latent Tuberculosis. <i>Journal of Immigrant and Minority Health</i> , 2018, 20, 687-696.	0.8	5
133	Development of resistance to Mycobacterium tuberculosis is manageable in hidradenitis suppurativa. Response to "Treatment of hidradenitis suppurativa with rifampicin: have we forgotten tuberculosis?" TM . <i>British Journal of Dermatology</i> , 2018, 178, 300-300.	1.4	4
134	Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 20-29.	1.4	17
135	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: Management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 30-36.	1.4	20
136	Implementation of tuberculosis prevention for exposed children, Burkina Faso. <i>Bulletin of the World Health Organization</i> , 2018, 96, 386-392.	1.5	4
137	Screening for Latent Tuberculosis Infection in Patients with Autoimmune Diseases Before Initiating TNF- and #945; Inhibitors Therapy. <i>Materia Socio-medica</i> , 2018, 30, 32.	0.3	0
138	Comparative sensitivity of the test with tuberculosis recombinant allergen, containing ESAT6-CFP10 protein, and Mantoux test with 2 TU PPD-L in newly diagnosed tuberculosis children and adolescents in Moscow. <i>PLoS ONE</i> , 2018, 13, e0208705.	1.1	23
140	Eliminating tuberculosis in Latin America: making it the point. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 73-76.	0.4	10
141	Three-month weekly rifapentine plus isoniazid for tuberculosis preventive treatment: a systematic review. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1422-1428.	0.6	36
142	A scoring strategy for progression risk and rates of treatment completion in subjects with latent tuberculosis. <i>PLoS ONE</i> , 2018, 13, e0207582.	1.1	4
143	Incidence of tuberculosis and the need of prophylactic treatment in persons living with HIV in Stockholm during the era of anti-retroviral therapy 1996-2013. <i>Infectious Diseases</i> , 2018, 50, 807-816.	1.4	5
144	Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. <i>BMC Infectious Diseases</i> , 2018, 18, 587.	1.3	20
145	Cost-effectiveness of contact screening strategies for tuberculosis among high-school adolescents in South Korea. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 496-503.	0.6	6
146	Treatment of latent tuberculosis infection among health care workers at a tertiary hospital in Korea. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 1336-1343.	0.6	8
147	Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2018, 13, 3-11.	0.5	18
148	Tuberculosis elimination in Oman: winning the war on the disease. <i>ERJ Open Research</i> , 2018, 4, 00121-2018.	1.1	7

#	ARTICLE	IF	CITATIONS
149	Investigating a tuberculosis cluster among Filipino health care workers in a low-incidence country. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 252-257.	0.6	3
150	Prevalence of tuberculosis and multidrug resistant tuberculosis in the Middle East Region. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 709-721.	2.0	22
151	Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection. <i>Scientific Reports</i> , 2018, 8, 15626.	1.6	23
152	Can we predict tuberculosis cure? What tools are available?. <i>European Respiratory Journal</i> , 2018, 52, 1801089.	3.1	73
153	National policies on the management of latent tuberculosis infection: review of 98 countries. <i>Bulletin of the World Health Organization</i> , 2018, 96, 173-184F.	1.5	36
154	Latent tuberculosis infection is associated with increased unstimulated levels of interferon-gamma in Lima, Peru. <i>PLoS ONE</i> , 2018, 13, e0202191.	1.1	12
156	The role of epigenetics, bacterial and host factors in progression of <i>Mycobacterium tuberculosis</i> infection. <i>Tuberculosis</i> , 2018, 113, 200-214.	0.8	46
158	A case report of mucocutaneous tuberculosis after orthotopic liver transplantation: a challenging diagnosis. <i>BMC Infectious Diseases</i> , 2018, 18, 431.	1.3	3
159	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management. <i>Intestinal Research</i> , 2018, 16, 17.	1.0	20
160	Lessons learned from two interventions designed to increase adherence to LTBI treatment in Latino youth. <i>Contemporary Clinical Trials Communications</i> , 2018, 12, 129-136.	0.5	7
161	Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. <i>Intestinal Research</i> , 2018, 16, 4.	1.0	32
162	Prognostic value of interferon- γ release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1077-1087.	4.6	135
163	Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support. <i>European Respiratory Journal</i> , 2018, 52, 1801363.	3.1	36
164	How effective are approaches to migrant screening for infectious diseases in Europe? A systematic review. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e259-e271.	4.6	99
165	Screening for tuberculosis in migrants and visitors from high-incidence settings: present and future perspectives. <i>European Respiratory Journal</i> , 2018, 52, 1800591.	3.1	37
166	Preparation, validation and user-testing of pictogram-based patient information leaflets for tuberculosis. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018, 51, 26-31.	1.1	5
167	Prevalence of and risk factors associated with latent tuberculosis in Singapore: A cross-sectional survey. <i>International Journal of Infectious Diseases</i> , 2018, 72, 55-62.	1.5	24
168	Data Mining <i>Mycobacterium tuberculosis</i> Pathogenic Gene Transcription Factors and Their Regulatory Network Nodes. <i>International Journal of Genomics</i> , 2018, 2018, 1-9.	0.8	6

#	ARTICLE	IF	CITATIONS
169	Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease. <i>Journal of Infection</i> , 2018, 77, 291-295.	1.7	18
170	Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. <i>PLoS ONE</i> , 2018, 13, e0196322.	1.1	20
171	Active case finding and treatment adherence in risk groups in the tuberculosis pre-elimination era. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 479-487.	0.6	16
172	Recommendations for the screening of paediatric latent tuberculosis infection in indigenous communities: a systematic review of screening strategies among high-risk groups in low-incidence countries. <i>BMC Public Health</i> , 2018, 18, 979.	1.2	7
173	Evidence-based consensus on opportunistic infections in inflammatory bowel disease (republication). <i>Intestinal Research</i> , 2018, 16, 178.	1.0	21
175	Lysophosphatidylcholine Promotes Phagosome Maturation and Regulates Inflammatory Mediator Production Through the Protein Kinase A-Phosphatidylinositol 3-Kinase-p38 Mitogen-Activated Protein Kinase Signaling Pathway During Mycobacterium tuberculosis Infection in Mouse Macrophages. <i>Frontiers in Immunology</i> , 2018, 9, 920.	2.2	71
176	Tuberculosis Specific Interferon-Gamma Production in a Current Refugee Cohort in Western Europe. <i>International Journal of Environmental Research and Public Health</i> , 2018, 15, 1263.	1.2	6
177	Bacterial Diseases of the Nervous System. , 2018, , 247-267.		0
178	Serial Tuberculin Skin Tests Improve the Detection of Latent Tuberculosis Infection in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1270-1279.	0.6	15
179	3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review. <i>European Respiratory Journal</i> , 2018, 52, 1800395.	3.1	17
180	Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients. <i>Journal of Clinical Microbiology</i> , 2018, 56, .	1.8	37
181	An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease. <i>European Respiratory Journal</i> , 2018, 52, 1800946.	3.1	27
183	Treatment of Tuberculosis Infection in Children. <i>Journal of Pediatric Infectious Diseases</i> , 2018, 13, 132-140.	0.1	0
184	Latent tuberculosis infection in foreign-born communities: Import vs. transmission in The Netherlands derived through mathematical modelling. <i>PLoS ONE</i> , 2018, 13, e0192282.	1.1	6
185	Tuberculosis elimination: where are we now?. <i>European Respiratory Review</i> , 2018, 27, 180035.	3.0	76
186	Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective. <i>Journal of Infection</i> , 2019, 78, 58-65.	1.7	9
187	Utility of tuberculin skin test and IGRA for tuberculosis screening in internationally adopted children: Retrospective analysis from a single center in Florence, Italy. <i>Travel Medicine and Infectious Disease</i> , 2019, 28, 64-67.	1.5	10
188	Migrant Healthcare Guidelines: A Systematic Quality Assessment. <i>Journal of Immigrant and Minority Health</i> , 2019, 21, 401-413.	0.8	9

#	ARTICLE	IF	CITATIONS
189	Pulmonary Complications in the Immunocompromised Host. , 2019, , 337-349.		0
190	Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. <i>Journal of Microbiology, Immunology and Infection</i> , 2019, 52, 158-162.	1.5	19
191	Should NICE reconsider the 2016 UK guidelines on TB contact tracing? A cost-effectiveness analysis of contact investigations in London. <i>Thorax</i> , 2019, 74, 185-193.	2.7	5
192	Contribution of QuantiFERON-TB Gold-in-Tube to the Diagnosis of Mycobacterium tuberculosis Infection in Young Children in a Low TB Prevalence Country. <i>Frontiers in Pediatrics</i> , 2019, 7, 291.	0.9	7
193	The burdens of tuberculosis on patients with malignancy: incidence, mortality and relapse. <i>Scientific Reports</i> , 2019, 9, 11901.	1.6	35
194	Spatial analysis of HIV-TB co-clustering in Uganda. <i>BMC Infectious Diseases</i> , 2019, 19, 612.	1.3	24
195	An evaluation of a tuberculosis case-finding and treatment program among Syrian refugees in Jordan and Lebanon, 2013-2015. <i>Conflict and Health</i> , 2019, 13, 32.	1.0	12
197	Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: Comprehensive review. <i>Transplant Infectious Disease</i> , 2019, 21, e13178.	0.7	17
198	Latent tuberculosis infection and associated risk factors among people living with HIV and apparently healthy blood donors at the University of Gondar referral hospital, Northwest Ethiopia. <i>BMC Research Notes</i> , 2019, 12, 515.	0.6	9
199	Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. , 2019, 7, 239.		81
200	QuantiFERON TB Gold Plus for the diagnosis of tuberculosis: a systematic review and meta-analysis. <i>Journal of Infection</i> , 2019, 79, 444-453.	1.7	64
201	Tuberculosis in people with rheumatic disease in Finland 1995-2007: a nationwide retrospective register study. <i>Rheumatology Advances in Practice</i> , 2019, 3, rkz020.	0.3	10
202	Post-bacterial infection chronic fatigue syndrome is not a latent infection. <i>Médecine Et Maladies Infectieuses</i> , 2019, 49, 140-149.	5.1	12
203	Update upon the infection risk in patients receiving TNF alpha inhibitors. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 219-229.	1.0	37
204	Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area. <i>European Respiratory Journal</i> , 2019, 53, 1802077.	3.1	28
205	Pellagra in isoniazid preventive and antiretroviral therapy. <i>IDCases</i> , 2019, 17, e00550.	0.4	18
206	Characterization of G-Quadruplex Motifs in espB, espK, and cyp51 Genes of Mycobacterium tuberculosis as Potential Drug Targets. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 16, 698-706.	2.3	44
207	British HIV Association guidelines for the management of tuberculosis in adults living with HIV. <i>HIV Medicine</i> , 2019, 20, s2-s83.	1.0	8

#	ARTICLE	IF	CITATIONS
208	Shorter regimens in treatment of latent tuberculosisâ€”is it effective?. Current Medicine Research and Practice, 2019, 9, 35-36.	0.1	0
209	Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office forÂEurope. European Respiratory Journal, 2019, 53, 1900391.	3.1	81
210	Regional success on screening and chemoprophylaxis in contacts of patients with pulmonary tuberculosis in Turkey: a dispensary experience in 2016â€”2017. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 351-355.	0.7	0
211	Mycobacterial Infections in Patients With Chronic Kidney Disease and Kidney Transplantation. Advances in Chronic Kidney Disease, 2019, 26, 35-40.	0.6	15
212	<i>Mycobacterium tuberculosis</i> infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clinical Transplantation, 2019, 33, e13513.	0.8	100
213	Prevalence of latent tuberculosis in homeless persons: A single-centre cross-sectional study, Germany. PLoS ONE, 2019, 14, e0214556.	1.1	8
214	Building a European database to gather multi-country evidence on active and latent TB screening for migrants. International Journal of Infectious Diseases, 2019, 80, S45-S49.	1.5	9
215	Can treatment outcomes of latent TB infection and TB in silicosis be improved?. Journal of Thoracic Disease, 2019, 11, E8-E10.	0.6	5
216	Diagnostic pathways and delay among tuberculosis patients in Stockholm, Sweden: a retrospective observational study. BMC Public Health, 2019, 19, 151.	1.2	4
217	The Migrant Traveler. , 2019, , 331-334.		1
218	Tuberculosis in Children. Pediatrics in Review, 2019, 40, 168-178.	0.2	25
219	Latent tuberculosis infection in transplant candidates: a systematic review and meta-analysis on TST and IGRA. Infection, 2019, 47, 353-361.	2.3	23
220	Mania induced by isoniazid preventive therapy during steroid treatment for rheumatoid arthritis and organising pneumonia. BMJ Case Reports, 2019, 12, e231919.	0.2	3
221	Comparison of QFT-Plus and QFT-GIT tests for diagnosis of M. tuberculosis infection in immunocompetent Korean subjects. Journal of Thoracic Disease, 2019, 11, 5210-5217.	0.6	16
222	Global tuberculosis prevention: should we start from the beginning?. European Respiratory Journal, 2019, 54, 1901394.	3.1	9
223	The latent tuberculosis infection cascade of care in Iqaluit, Nunavut, 2012â€”2016. BMC Infectious Diseases, 2019, 19, 890.	1.3	17
224	Treatment of Latent Tuberculosis Infectionâ€”An Update. Clinics in Chest Medicine, 2019, 40, 839-848.	0.8	30
225	Management of Children with Tuberculosis. Clinics in Chest Medicine, 2019, 40, 797-810.	0.8	8

#	ARTICLE	IF	CITATIONS
226	Screening for latent tuberculosis in patients with inflammatory bowel disease under antitumor necrosis factor: data from a Portuguese center. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1099-1102.	0.8	5
227	Prophylaxis for Tuberculosis in Pregnant Women. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 846-856.	0.6	1
228	Predicting the artificial immunity induced by RUTIÂ® vaccine against tuberculosis using universal immune system simulator (UISS). <i>BMC Bioinformatics</i> , 2019, 20, 504.	1.2	27
229	The T-SPOT.TB assay used for screening and monitoring of latent tuberculosis infection in patients with Behçet's disease pre- and post-anti-TNF treatment. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 375-380.	0.6	9
230	Treatment of latent tuberculosis with 12 weeks isoniazid/rifapentine in clinical practice. <i>European Respiratory Journal</i> , 2019, 53, 1801128.	3.1	6
231	Accuracy of interferon-Î³-induced protein 10 for diagnosing latent tuberculosis infection: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2019, 25, 667-672.	2.8	18
232	Tuberculosis Elimination, Research, and Respect for Persons. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 560-563.	2.5	7
233	Screening of healthcare workers for latent tuberculosis infection in the low tuberculosis burden country: QuantiFERON-TB gold in tube test or tuberculin skin test?. <i>Archives of Environmental and Occupational Health</i> , 2019, 74, 109-114.	0.7	8
234	Latent tuberculosis infection screening in HIV-infected patients: guidelines versus everyday practice in a UK HIV centre. <i>HIV Medicine</i> , 2019, 20, e3-e4.	1.0	1
235	Factors affecting TST level in patients undergoing dialysis: a multicenter study. <i>Hemodialysis International</i> , 2019, 23, 81-87.	0.4	6
236	Mycobacterium tuberculosis: active disease and latent infection in a renal transplant cohort. <i>Nephrology</i> , 2019, 24, 569-574.	0.7	10
237	High rate of indeterminate results of the QuantiFERON-TB Gold in-tube test, third generation, in patients with systemic vasculitis. <i>Rheumatology</i> , 2020, 59, 1006-1010.	0.9	7
238	Determinants of Latent Tuberculosis Treatment Acceptance and Completion in Healthcare Personnel. <i>Clinical Infectious Diseases</i> , 2020, 71, 284-290.	2.9	11
239	A rare case of multi-focal human TB after BCG instillation for non-muscle-invasive bladder cancer. <i>Urologia</i> , 2020, 87, 199-202.	0.3	2
240	High risk of activation of latent tuberculosis infection in rheumatic disease patients. <i>Infectious Diseases</i> , 2020, 52, 80-86.	1.4	15
241	Immune checkpoint inhibitors and tuberculosis: an old disease in a new context. <i>Lancet Oncology</i> , The, 2020, 21, e55-e65.	5.1	59
242	A high C-reactive protein level and poor performance status are associated with delayed sputum conversion in elderly patients with pulmonary tuberculosis in Japan. <i>Clinical Respiratory Journal</i> , 2020, 14, 291-298.	0.6	5
243	Prevention and treatment of tuberculosis in solid organ transplant recipients. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 63-73.	2.0	14

#	ARTICLE	IF	CITATIONS
244	Treatment for latent tuberculosis infection in low- and middle-income countries: progress and challenges with implementation and scale-up. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 195-208.	1.0	15
245	Ending TB in Australia: Organizational challenges for regional tuberculosis programs. <i>Health Policy</i> , 2020, 124, 106-112.	1.4	9
246	Host factors associated to false negative and indeterminate results in an interferon- γ release assay in patients with active tuberculosis. <i>Pulmonology</i> , 2020, 26, 353-362.	1.0	23
247	Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. <i>Clinical Infectious Diseases</i> , 2020, 71, 1320-1323.	2.9	5
248	Incidence of and risk factors for tuberculosis among people with HIV on antiretroviral therapy in the United Kingdom. <i>Aids</i> , 2020, 34, 1813-1821.	1.0	8
249	Risk factors affecting the failure to complete treatment for patients with latent tuberculosis infection in Tokyo, Japan. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 1129-1133.	0.8	0
250	Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings. <i>Nature Medicine</i> , 2020, 26, 1941-1949.	15.2	58
251	Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January–April 2020. <i>Emerging Infectious Diseases</i> , 2020, 26, 2709-2712.	2.0	133
252	Evaluation of cytokines as a biomarker to distinguish active tuberculosis from latent tuberculosis infection: a diagnostic meta-analysis. <i>BMJ Open</i> , 2020, 10, e039501.	0.8	8
253	Spatial Pattern and Associated Factors of ANC Visits in Ethiopia: Spatial and Multilevel Modeling of Ethiopian Demographic Health Survey Data. <i>Advances in Preventive Medicine</i> , 2020, 2020, 1-13.	1.1	9
254	Active household contact screening for tuberculosis and provision of isoniazid preventive therapy to under-five children in Afghanistan. <i>PLoS ONE</i> , 2020, 15, e0240031.	1.1	6
255	New vaccine candidates as a scientific solution against the dream of tuberculosis vaccine. <i>Reviews in Medical Microbiology</i> , 2020, 31, 126-134.	0.4	3
256	A Targeted Screening Program for Latent Tuberculosis Infection Among Hematopoietic Cell Transplant Recipients. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa224.	0.4	1
257	Serial testing of health care workers for tuberculosis infection: A prospective cohort study. <i>PLoS ONE</i> , 2020, 15, e0235986.	1.1	4
258	Comparison of QuantiFERON-TB Gold Plus, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB among patients with tuberculosis. <i>Journal of Infection and Chemotherapy</i> , 2020, 26, 1205-1212.	0.8	14
259	Predictive performance of interferon- γ release assays and tuberculin skin tests. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 1371-1372.	4.6	2
260	Is interleukin-2 an optimal marker for diagnosing tuberculosis infection? A systematic review and meta-analysis. <i>Annals of Medicine</i> , 2020, 52, 376-385.	1.5	10
261	Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study. <i>Annals of Hematology</i> , 2020, 99, 2201-2203.	0.8	3

#	ARTICLE	IF	CITATIONS
262	Tuberculosis preventive treatment should be considered for all household contacts of pulmonary tuberculosis patients in India. <i>PLoS ONE</i> , 2020, 15, e0236743.	1.1	16
263	Tuberculosis Skin Test Screening in the National Tuberculosis Program of Trinidad and Tobago. <i>Healthcare (Switzerland)</i> , 2020, 8, 236.	1.0	0
264	Tuberculosis Screening, Testing, and Treatment of US Health Care Personnel. <i>Journal of Occupational and Environmental Medicine</i> , 2020, 62, e355-e369.	0.9	3
265	CD4 response of QuantiFERON-TB Gold Plus for positive consistency of latent tuberculosis infection in patients on dialysis. <i>Scientific Reports</i> , 2020, 10, 21367.	1.6	4
266	Active tuberculosis risk associated with malignancies: an 18-year retrospective cohort study in Korea. <i>Journal of Thoracic Disease</i> , 2020, 12, 4950-4959.	0.6	9
267	Tuberculosis among Patients Undergoing Solid Organ Transplantation or Dialysis in a Low-Endemic Country, 2004-2017. <i>Tuberculosis Research and Treatment</i> , 2020, 2020, 1-7.	0.2	4
268	Cost effectiveness of testing HIV infected individuals for TB in a low TB/HIV setting. <i>Journal of Infection</i> , 2020, 81, 289-296.	1.7	10
269	Screening migrants from tuberculosis high-endemic countries for latent tuberculosis in Oman: A cross sectional cohort analysis. <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101734.	1.5	5
270	Latent tuberculosis infection screening and treatment in congregate settings (TB FREE COREA): protocol for a prospective observational study in Korea. <i>BMJ Open</i> , 2020, 10, e034098.	0.8	7
271	Autoimmune mucocutaneous blistering diseases in the south of Italy: a 25-year retrospective study on 169 patients. <i>Journal of Oral Pathology and Medicine</i> , 2020, 49, 672-680.	1.4	8
272	The Great Masquerader: Tuberculosis Presenting as Community-Acquired Pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 592-604.	0.8	11
273	Latent tuberculosis infection and the EndTB Strategy: ethical tensions and imperatives. <i>International Journal of Tuberculosis and Lung Disease</i> , 2020, 24, 21-26.	0.6	12
274	CD4+ T cell proliferative responses to PPD and CFP-10 associate with recent <i>M. tuberculosis</i> infection. <i>Tuberculosis</i> , 2020, 123, 101959.	0.8	3
275	Systematic review on tuberculosis risk in patients with rheumatoid arthritis receiving inhibitors of Janus Kinases. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 861-872.	1.0	24
276	Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection. <i>PLoS ONE</i> , 2020, 15, e0234700.	1.1	6
277	Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre. <i>Lung Cancer</i> , 2020, 146, 145-153.	0.9	14
278	Delivering multi-disease screening to migrants for latent TB and blood-borne viruses in an emergency department setting: A feasibility study. <i>Travel Medicine and Infectious Disease</i> , 2020, 36, 101611.	1.5	11
279	Impact of comorbidities on the performance of interferon-gamma release assay in an elderly Greek population without overt immunodeficiency. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106073.	1.1	1

#	ARTICLE	IF	CITATIONS
280	Impact of Effective Global Tuberculosis Control on Health and Economic Outcomes in the United States. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1567-1575.	2.5	14
281	Latent Tuberculosis Infection Increases in Kidney Transplantation Recipients Compared With Transplantation Candidates: A Neglected Perspective in Tuberculosis Control. <i>Clinical Infectious Diseases</i> , 2020, 71, 914-923.	2.9	13
282	In Silico Strategies in Tuberculosis Drug Discovery. <i>Molecules</i> , 2020, 25, 665.	1.7	50
283	Global tuberculosis research and its future prospects. <i>Tuberculosis</i> , 2020, 121, 101917.	0.8	32
284	Clinical Development of New TB Vaccines: Recent Advances and Next Steps. <i>Frontiers in Microbiology</i> , 2019, 10, 3154.	1.5	56
285	Risk of active tuberculosis development in contacts exposed to infectious tuberculosis in congregate settings in Korea. <i>Scientific Reports</i> , 2020, 10, 1306.	1.6	7
286	Tools to implement the World Health Organization End TB Strategy: Addressing common challenges in high and low endemic countries. <i>International Journal of Infectious Diseases</i> , 2020, 92, S60-S68.	1.5	26
287	The impact on incident tuberculosis by kidney function impairment status: analysis of severity relationship. <i>Respiratory Research</i> , 2020, 21, 51.	1.4	8
288	Tuberculin skin test and predictive host factors for false-negative results in patients with pulmonary and extrapulmonary tuberculosis. <i>Clinical Respiratory Journal</i> , 2020, 14, 541-548.	0.6	6
289	Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. <i>PLoS Medicine</i> , 2020, 17, e1003008.	3.9	74
290	Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations. <i>European Respiratory Journal</i> , 2020, 55, 1901957.	3.1	30
291	Can Interferon- γ Release Assays Be Useful for Monitoring the Response to Anti-tuberculosis Treatment?: A Systematic Review and Meta-analysis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 4.	1.0	7
292	Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1744-1749.	1.3	22
293	KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. <i>Transplantation</i> , 2020, 104, S11-S103.	0.5	306
294	Fluorogenic Probes/Inhibitors of β -Lactamase and their Applications in Drug-Resistant Bacteria. <i>Angewandte Chemie</i> , 2021, 133, 24-40.	1.6	3
295	Fluorogenic Probes/Inhibitors of β -Lactamase and their Applications in Drug-Resistant Bacteria. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 24-40.	7.2	38
296	High reproducibility of the interferon-gamma release assay T-SPOT.TB in serial testing. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 85-93.	1.3	2
297	Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la infección tuberculosa en pacientes con enfermedad inflamatoria intestinal. <i>Gastroenterología Y Hepatología</i> , 2021, 44, 51-66.	0.2	5

#	ARTICLE	IF	CITATIONS
298	Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view. <i>Tuberculosis</i> , 2021, 126, 102041.	0.8	1
299	The paradigm shift in the approach to management of latent tuberculosis infection in high tuberculosis burden countries. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 899-910.	1.0	1
300	Evaluation of the latent tuberculosis screening and treatment strategy for asylum seekers in Stockholm, Sweden 2015-2018: a record linkage study of the care cascade. <i>European Respiratory Journal</i> , 2021, 57, 2002255.	3.1	3
301	Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110284.	1.1	5
303	<i>Mycobacterium tuberculosis</i> in Transplantation. , 2021, , 409-423.		0
304	Framework for the evaluation of new tests for tuberculosis infection. <i>European Respiratory Journal</i> , 2021, 58, 2004078.	3.1	9
305	Tuberculosis and Migration. , 2021, , 203-211.		1
306	Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on screening and treatment of tuberculosis infection in patients with inflammatory bowel disease. <i>GastroenterologĀa Y HepatologĀa (English Edition)</i> , 2021, 44, 51-66.	0.0	4
307	Structure prediction, molecular simulations of RmlD from <i>Mycobacterium tuberculosis</i> , and interaction studies of Rhodanine derivatives for anti-tuberculosis activity. <i>Journal of Molecular Modeling</i> , 2021, 27, 75.	0.8	5
309	Closing delivery gaps in the treatment of tuberculosis infection: Lessons from implementation research in Peru. <i>PLoS ONE</i> , 2021, 16, e0247411.	1.1	5
310	Completion and Adverse Drug Events of Latent Tuberculosis Infection Treatment in Patients Receiving Dialysis: Predictors and Impacts of Different Regimens in a Prospective Cohort Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	4
311	Vaccine-preventable diseases other than tuberculosis, and homelessness: A scoping review of the published literature, 1980 to 2020. <i>Vaccine</i> , 2021, 39, 1205-1224.	1.7	10
312	Guidelines on controlling latent tuberculosis infection to support tuberculosis elimination. <i>Revista EspaĀola De Sanidad Penitenciaria</i> , 2021, 23, 28-36.	0.5	4
313	Deletion of <i>pknG</i> Abates Reactivation of Latent <i>Mycobacterium tuberculosis</i> in Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	11
314	Health economic analyses of latent tuberculosis infection screening and preventive treatment among people living with HIV in lower tuberculosis incidence settings: a systematic review. <i>Wellcome Open Research</i> , 0, 6, 51.	0.9	0
315	Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL. <i>Cancers</i> , 2021, 13, 1280.	1.7	14
316	Is the New Interferon-Gamma Releasing Assay Beneficial for the Diagnosis of Latent and Active <i>Mycobacterium tuberculosis</i> Infections in Tertiary Care Setting?. <i>Journal of Clinical Medicine</i> , 2021, 10, 1376.	1.0	10
317	Validation of Differentially Expressed Immune Biomarkers in Latent and Active Tuberculosis by Real-Time PCR. <i>Frontiers in Immunology</i> , 2020, 11, 612564.	2.2	16

#	ARTICLE	IF	CITATIONS
318	Erythema Multiforme-like Dermatitis Due to Isoniazid Hypersensitivity in a Patient With Psoriasis. , 2021, 107, E33-E36.		0
319	Pulmonary Tuberculosis and Management of Contact Patients in a Department of Nephrology and Kidney Transplantation. International Journal of Infectious Diseases, 2021, , .	1.5	2
320	Functional Polymorphism in the NFE2L2 Gene Associated With Tuberculosis Susceptibility. Frontiers in Immunology, 2021, 12, 660384.	2.2	7
321	Human tuberculosis and Mycobacterium tuberculosis complex: A review on genetic diversity, pathogenesis and omics approaches in host biomarkers discovery. Microbiological Research, 2021, 246, 126674.	2.5	55
322	Tuberculosis Risk Stratification of Psoriatic Patients Before Anti-TNF- α Treatment. Frontiers in Immunology, 2021, 12, 672894.	2.2	3
323	Atypical lymphadenopathy in a patient with squamous cell carcinoma of the tongue: TB or not TB?. Advances in Oral and Maxillofacial Surgery, 2021, 3, 100100.	0.1	0
324	Tuberculosis contacts study: Organization and prevalence of latent tuberculosis infection. Archivos De Bronconeumologia, 2021, 57, 509-511.	0.4	0
325	The role of exosomes from BALF in lung disease. Journal of Cellular Physiology, 2022, 237, 161-168.	2.0	31
326	Hepatotoxicity, efficacy and completion rate between 3 months of isoniazid plus rifapentine and 9 months of isoniazid in treating latent tuberculosis infection: A systematic review and meta-analysis. Journal of the Chinese Medical Association, 2021, 84, 993-1000.	0.6	8
327	Tuberculosis incidence and mortality in people living with human immunodeficiency virus: a Danish nationwide cohort study. Clinical Microbiology and Infection, 2022, 28, 570-579.	2.8	4
328	Latent tuberculosis infection and kidney transplantation. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, , .	0.4	0
329	The definition of tuberculosis infection based on the spectrum of tuberculosis disease. Breathe, 2021, 17, 210079.	0.6	59
330	Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening. BMC Infectious Diseases, 2021, 21, 936.	1.3	2
331	Identifying factors affecting latent tuberculosis treatment acceptance among healthcare workers: a retrospective analysis in a tertiary care centre. BMJ Open, 2021, 11, e047444.	0.8	1
332	Tuberculosis Screening in Silica-Exposed Workers. Public Health Reports, 2021, , 003335492110415.	1.3	0
333	Trend and treatment outcomes of latent tuberculosis infection among migrant persons in Japan: retrospective analysis of Japan tuberculosis surveillance data. BMC Infectious Diseases, 2021, 21, 42.	1.3	5
334	Tuberculosis and comorbidities. , 0, , 276-290.		2
335	Does phone messaging improves tuberculosis treatment success? A systematic review and meta-analysis. BMC Infectious Diseases, 2020, 20, 42.	1.3	21

#	ARTICLE	IF	CITATIONS
336	Lessons learned from continued TB outbreaks in a high school. <i>PLoS ONE</i> , 2017, 12, e0188076.	1.1	5
337	Latent tuberculosis infection: An overview. <i>Canada Communicable Disease Report</i> , 2017, 43, 62-66.	0.6	120
338	Essential Components of a Public Health Tuberculosis Prevention, Control, and Elimination Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis and the National Tuberculosis Controllers Association. <i>MMWR Recommendations and Reports</i> , 2020, 69, 1-27.	26.7	34
339	Elevated Circulating Concentrations of Interferon-Gamma in Latent Tuberculosis Infection. <i>Pathogens and Immunity</i> , 2016, 1, 291.	1.4	18
340	Estimating Tuberculin Skin Test Reactions among Children and Teenagers Who Received the Bacillus Calmette-Guerin Vaccination at Birth: A Meta-analysis. <i>Osong Public Health and Research Perspectives</i> , 2017, 8, 3-10.	0.7	3
341	Prevention of tuberculosis in household members: estimates of children eligible for treatment. <i>Bulletin of the World Health Organization</i> , 2019, 97, 534-547D.	1.5	17
342	Current status of treatment of latent tuberculosis infection in India. <i>Indian Journal of Medical Sciences</i> , 0, 71, 54-59.	0.1	12
343	Identifying components for programmatic latent tuberculosis infection control in the European Union. <i>Eurosurveillance</i> , 2016, 21, .	3.9	12
344	The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. <i>Eurosurveillance</i> , 2018, 23, .	3.9	25
345	The Strategic Plan for Control of Tuberculosis in Australia, 2016â€“2020: Towards Disease Elimination. <i>Communicable Diseases Intelligence (2018)</i> , 0, 43, .	0.3	10
346	Screening for latent tuberculosis infections at the beginning of hemodialysis in our hospital. <i>Nihon Toseki Igakkai Zasshi</i> , 2018, 51, 599-605.	0.2	1
347	Vitamin D supplementation as a control program against latent tuberculosis infection in Korean high school students. <i>Epidemiology and Health</i> , 2018, 40, e2018035.	0.8	4
348	Overweight, Obesity, and Older Age Favor Latent Tuberculosis Infection among Household Contacts in Low Tuberculosis-Incidence Settings within Panama. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1141-1144.	0.6	11
349	Determinants of latent tuberculosis infection and treatment interruption in long-term care facilities: A retrospective cohort study in Taiwan. <i>Journal of Microbiology, Immunology and Infection</i> , 2021, , .	1.5	1
350	Pulmonary Complications in the Immunocompromised Host. , 2014, , 331-343.		0
351	Stage 1 screenings of periodical health check: A systematic review of long-term efficiency. <i>Profilakticheskaya Meditsina</i> , 2017, 20, 55.	0.2	1
352	An opposing view on including high school students in a latent tuberculosis infection control program in Korea. <i>Epidemiology and Health</i> , 2017, 39, e2017015.	0.8	5
355	Clinical presentation of tuberculosis: a nine-year single-center experience. <i>The European Research Journal</i> , 2018, 4, 211-214.	0.1	2

#	ARTICLE	IF	CITATIONS
357	Mixed methods study on elimination of tuberculosis in Hong Kong. Hong Kong Medical Journal, 2018, 24, 400-7.	0.1	3
358	Tuberculosis in immunocompromised patients. , 2019, , 429-432.		0
359	Management and outcomes of severe childhood tuberculosis in the pediatric intensive care setting: can we identify best practices?. Jornal Brasileiro De Pneumologia, 2019, 45, e20190043.	0.4	5
360	Prevalence and Risk Factors of Latent Tuberculosis Infection among Healthcare Workers. Korean Journal of Healthcare-Associated Infection Control and Prevention, 2019, 24, 52.	0.1	3
361	THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE. Tuberculosis and Lung Diseases, 2019, 96, 55-61.	0.2	2
362	Diagnosis and Treatment of Latent Tuberculosis Infection for Healthcare Workers. Korean Journal of Healthcare-Associated Infection Control and Prevention, 2019, 24, 43.	0.1	0
363	From control of tuberculosis to control of infection: WHO recommendations for low-prevalence countries. Revista Española De Sanidad Penitenciaria, 2019, 21, 1-4.	0.5	0
364	What is the best treatment for latent tuberculosis infection?. Evidence-Based Practice, 2019, 22, 22-23.	0.0	0
365	TIME SERIES ANALYSIS FOR FORECASTING THE NUMBER OF TUBERCULOSIS IN KENDARI CITY 2018-2023. Indonesian Journal of Health Sciences Research and Development (ijhsrd), 2019, 1, 72-79.	0.1	0
366	Prevalence of infectious diseases in patients with autoimmune blistering diseases. Journal of Dermatology, 2020, 47, 378-384.	0.6	2
368	Incidence of latent tuberculosis infection among health science students during clinical training. Annals of Thoracic Medicine, 2020, 15, 33.	0.7	1
369	Prevalence of Latent Tuberculosis (LTB) among Household Contacts of Newly Diagnosed Omani Pulmonary Tuberculosis Patients. Journal of Tuberculosis Research, 2020, 08, 11-21.	0.1	0
370	The relationship between social risk factors and latent tuberculosis infection among individuals residing in England: a cross-sectional study. BMJ Global Health, 2020, 5, e003550.	2.0	4
371	Estudio de contactos de pacientes con tuberculosis: organizaci3n y prevalencia de la infecci3n tuberculosa latente. Archivos De Bronconeumologia, 2021, 57, 509-511.	0.4	2
372	Mycobacteria and immunosuppression. Handbook of Systemic Autoimmune Diseases, 2020, 16, 83-107.	0.1	2
373	Mycobacterium tuberculosis in Transplantation. , 2020, , 1-16.		2
374	Defining the Optimal Threshold for Latent Tuberculosis Infection Testing for People Living with HIV: Results of a UK Screening Programme. SSRN Electronic Journal, 0, , .	0.4	0
375	Isolated gallbladder tuberculosis mimicking acute cholecystitis: A case report. World Journal of Gastrointestinal Surgery, 2020, 12, 123-128.	0.8	1

#	ARTICLE	IF	CITATIONS
376	Use of biologic agents and risk of tuberculosis in Brazil, a tuberculosis high-burden country. <i>Drugs in Context</i> , 2020, 9, 1-7.	1.0	3
377	Diagnosis and treatment of latent tuberculosis infection. , 0, , 381-398.		1
378	Behçet's disease with latent Mycobacterium tuberculosis infection. <i>Open Medicine (Poland)</i> , 2020, 16, 14-22.	0.6	3
379	Collaborative tuberculosis/HIV activities in the European Region. <i>ERJ Open Research</i> , 2021, 7, 00721-2020.	1.1	4
380	A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care. <i>Topics in Antiviral Medicine</i> , 2017, 24, 142-151.	0.1	0
381	From control of tuberculosis to control of infection: WHO recommendations for low-prevalence countries. <i>Revista Española De Sanidad Penitenciaria</i> , 2019, 21, 1-4.	0.5	0
382	Tuberculosis and TNF- α inhibitors in children: how to manage a fine balance. <i>Acta Biomedica</i> , 2020, 91, e2020009.	0.2	0
386	Interferon-Gamma Releasing Assay is Predictive in Active Tuberculosis Infection in Kidney Recipients and Guides Precise Prophylaxis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
387	Positive Rates of Interferon- γ Release Assay and Tuberculin Skin Test in Detection of Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis of 200,000 Head-to-Head Comparative Tests. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
388	Prevalence of Latent Tuberculosis Infection in Patients With Nontuberculous Mycobacterial Lung Disease and Colonization: A Prospective Study in an Intermediate Tuberculosis Burden Country. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac072.	0.4	2
389	How mycobacterium tuberculosis infection could lead to the increasing risks of chronic fatigue syndrome and the potential immunological effects: a population-based retrospective cohort study. <i>Journal of Translational Medicine</i> , 2022, 20, 99.	1.8	6
390	Not Only COVID-19: Prevalence and Management of Latent Mycobacterium Tuberculosis Infection in Three Penitentiary Facilities in Southern Italy. <i>Healthcare (Switzerland)</i> , 2022, 10, 386.	1.0	6
391	Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy. <i>Global Medical Genetics</i> , 2022, 09, 090-096.	0.4	3
392	The role of IGRA in the diagnosis of tuberculosis infection, differentiating from active tuberculosis, and decision making for initiating treatment or preventive therapy of tuberculosis infection. <i>International Journal of Infectious Diseases</i> , 2022, 124, S12-S19.	1.5	42
393	Update of the mechanism and characteristics of tuberculosis in chronic kidney disease. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 501-510.	1.0	1
394	AN INSIGHT INTO PRIVILEGED SCAFFOLDS IN TUBERCULOSIS: DEVELOPMENTAL ASPECTS AND IMPLICATIONS IN DRUG DESIGN. <i>Indian Drugs</i> , 2022, 59, 7-22.	0.1	0
395	A change in the timing of the Bacillus Calmette-Guérin vaccination in 2013 was associated with an increase in the incidence rate of infants with latent tuberculosis infection. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	0
396	Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study. <i>PLOS Global Public Health</i> , 2021, 1, e0000017.	0.5	3

#	ARTICLE	IF	CITATIONS
397	Joint Associations of Multiple Lifestyle Factors With Risk of Active Tuberculosis in the Population: The Singapore Chinese Health Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 213-220.	2.9	2
398	Randomised controlled trial to evaluate the effectiveness of using the RD-1-based C-Tb skin test as a replacement for blood-based interferon- γ release assay for detection of, and initiation of preventive treatment for, tuberculosis infection: RID-TB:Dx study protocol. <i>BMJ Open</i> , 2021, 11, e050595.	0.8	0
399	Tuberculosis incidence in country of origin is a key determinant of the risk of active tuberculosis in people living with HIV: Data from a 30-year observational cohort study. <i>HIV Medicine</i> , 2021, , .	1.0	4
400	Latent Tuberculosis Infection Diagnosis among Household Contacts in a High Tuberculosis-Burden Area: a Comparison between Transcript Signature and Interferon Gamma Release Assay. <i>Microbiology Spectrum</i> , 2022, 10, e0244521.	1.2	4
411	Treatment in Latent Tuberculosis Uveitis—Is Immunosuppression Effective or Is Conventional 3- or 4-Drug Antituberculosis Therapy Mandatory?. <i>Journal of Clinical Medicine</i> , 2022, 11, 2419.	1.0	3
412	The Association Between Diabetes Mellitus and the Risk of Latent Tuberculosis Infection: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 899821.	1.2	12
413	Prevalence trends of latent tuberculosis infection at the global, regional, and country levels from 1990–2019. <i>International Journal of Infectious Diseases</i> , 2022, 122, 46-62.	1.5	25
414	Reproducibility of a protocol for standardized reading of chest X-rays of children household contact of patients with tuberculosis. <i>BMC Pediatrics</i> , 2022, 22, .	0.7	0
415	A narrative review of tuberculosis in the United States among persons aged 65 years and older. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2022, 28, 100321.	0.6	8
416	Pilot study to identify missed opportunities for prevention of childhood tuberculosis. <i>European Journal of Pediatrics</i> , 2022, 181, 3299-3307.	1.3	2
417	Diagnosis and treatment of tuberculosis infection: can it contribute to achieving tuberculosis elimination?. <i>European Respiratory Journal</i> , 2022, 60, 2200540.	3.1	0
418	Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?. <i>Children</i> , 2022, 9, 1120.	0.6	9
419	The Potential Role of Vitamin D in the Development of Tuberculosis in Chinese Han Population: One Case-Control Study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
420	Screening of latent tuberculosis infection among patients with diabetes mellitus from a high-burden area in Brazil. <i>Frontiers in Clinical Diabetes and Healthcare</i> , 0, 3, .	0.3	1
421	The impact, effectiveness and outcomes of targeted screening thresholds for programmatic latent tuberculosis infection testing in HIV. <i>Aids</i> , 2022, 36, 2035-2044.	1.0	4
423	The cascade of care for latent tuberculosis infection in congregate settings: A national cohort analysis, Korea, 2017–2018. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
424	Large gap between attitude and action in tuberculosis preventive treatment among tuberculosis-related healthcare workers in eastern China. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	2
425	Positive rates of interferon- γ release assay and tuberculin skin test in detection of latent tuberculosis infection: A systematic review and meta-analysis of 200,000 head-to-head comparative tests. <i>Clinical Immunology</i> , 2022, 245, 109132.	1.4	7

#	ARTICLE	IF	CITATIONS
426	Globalization and Antimicrobial Resistance: A Moving Target. <i>Clinical Laboratory Science: Journal of the American Society for Medical Technology</i> , 2018, 31, ascls.2018000489.	0.1	0
428	Progress on diagnosis and treatment of latent tuberculosis infection. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2022, 51, 691-696.	0.1	0
429	National policies for delivering tuberculosis, HIV and hepatitis B and C virus infection services for refugees and migrants among Member States of the WHO European Region. <i>Journal of Travel Medicine</i> , 2023, 30, .	1.4	7
430	Algorithms for Screening for Active Tuberculosis among Individuals with Latent Tuberculosis Infection in a Rural Community in China. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	0
431	Tuberculosis Infection in Children and Adolescents. <i>Pathogens</i> , 2022, 11, 1512.	1.2	3
432	Health economic analyses of latent tuberculosis infection screening and preventive treatment among people living with HIV in lower tuberculosis incidence settings: a systematic review. <i>Wellcome Open Research</i> , 0, 6, 51.	0.9	0
433	A scoping review on the risk of tuberculosis in specific population groups: can we expand the World Health Organization recommendations?. <i>European Respiratory Review</i> , 2023, 32, 220127.	3.0	4
434	Predictive performance of interferon-gamma release assays and the tuberculin skin test for incident tuberculosis: an individual participant data meta-analysis. <i>EClinicalMedicine</i> , 2023, 56, 101815.	3.2	12
435	Mouse Models for Mycobacterium tuberculosis Pathogenesis: Show and Do Not Tell. <i>Pathogens</i> , 2023, 12, 49.	1.2	3
436	Performance of Interferon- γ Release Assays in Patients with Mycobacterium kansasii Infection. <i>Infection and Drug Resistance</i> , 0, Volume 15, 7727-7732.	1.1	1
437	Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	6
438	Incidence and risk factors of tuberculosis in patients following gastrectomy or endoscopic submucosal dissection: a cohort analysis of country-level data. <i>Gastric Cancer</i> , 2023, 26, 405-414.	2.7	0
439	An update on tuberculosis. , 2023, , 515-524.		0
440	A tuberculosis epidemic model as a proxy for the assessment of the novel $\langle \text{mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="d1e1471" altimg="si4.svg" \rangle \langle \text{mml:mrow} \langle \text{mml:mi} \rangle M \langle \text{mml:mi} \rangle \langle \text{mml:mn} \rangle 72 \langle \text{mml:mn} \rangle \langle \text{mml:mo} \rangle / \langle \text{mml:mo} \rangle \langle \text{mml:mi} \rangle A \langle \text{mml:mi} \rangle \langle \text{mml:mi} \rangle S$ Communications in Nonlinear Science and Numerical Simulation, 2023, 120, 107162.	1.7	3
441	Protocol for pragmatic randomized clinical trial to evaluate the completion of treatment of latent Mycobacterium tuberculosis infection with Isoniazid in the 300 mg formulation. <i>PLoS ONE</i> , 2023, 18, e0281638.	1.1	0
442	Management of Tuberculosis Infection: Current Situation, Recent Developments and Operational Challenges. <i>Pathogens</i> , 2023, 12, 362.	1.2	6
443	Burden of Chronic Obstructive Pulmonary Disease Attributable to Tuberculosis: A Microsimulation Study. <i>American Journal of Epidemiology</i> , 2023, 192, 908-915.	1.6	1
444	Methylprednisolone Promotes Mycobacterium smegmatis Survival in Macrophages through NF- κ B/DUSP1 Pathway. <i>Microorganisms</i> , 2023, 11, 768.	1.6	3

#	ARTICLE	IF	CITATIONS
445	The Role of Epigenetics in the Development of Anti-Tuberculosis Drug Resistance. Integrated Science, 2023, , 905-936.	0.1	0
446	Relationship Between Pre-existing Cancer and Tuberculosis. Integrated Science, 2023, , 79-88.	0.1	0
449	Recent Developments in the Treatment of Bacterial Pneumonia. , 2023, , 275-305.		0
455	Host-pathogen interactions in the context of tuberculosis infection and disease. , 2023, , 34-50.		0
456	Diagnosis of tuberculosis infection. , 2023, , 139-150.		0
457	The Role of Digital Agriculture in Transforming Rural Areas Into Smart Villages. , 2023, , 57-78.		2